Abstract
A new series of 1,3,4-oxadiazole bearing pyrimidine-pyrazine derivatives (9a–j) was developed and examined for their preliminary anticancer effects against four human cancer cell lines such as PC3 &DU-145 (prostate cancer), A549 (lung cancer) and MCF-7 (breast cancer). The well-known chemotherapeutic agent as etoposide used as a positive control. The IC50 values range of target compounds from 0.05 ± 0.007 µM to 9.44 ± 5.36 µM, whereas positive control displayed values from 1.97 ± 0.45 µM to 3.08 ± 0.135 µM, respectively. Among them, five compounds (9a, 9b, 9c, 9g and 9j) exhibited most potent activities. Predominantly, one compound 9a showed superior activity.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
